CancerTYPE ID | A Widely Adopted Molecular Test for Metastatic Patients with Diagnostic Ambiguity

Latest News

MSI and MMR testing may now be ordered concurrently with
CancerTYPE ID^® to help with your metastatic cancer treatment planning.

Latest News

MSI and MMR testing may now be ordered concurrently with CancerTYPE ID^® to help with your metastatic cancer treatment planning.

Actionable genomic information for accurate diagnosis for metastatic patients with diagnostic ambiguity

Order Now

Key Attributes

Distinguishes between 50 tumor types

Requires small tumor sample (~300 cells)

Most widely adopted gene expression test

Results in 5-7 business days

Most validated gene expression test

100% covered by Medicare

Healthcare Professionals

Patients and Caregivers

CancerTYPE ID: Mechanism of Action

The Most Important Aspect to Treating Tumors

Laboratory photo

Photo of physician listening to patient